Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Overview 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Companies Involved in Therapeutics Development Intezyne Technologies Inc Nuevolution AB 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drug Profiles HA-15 - Drug Profile Product Description Mechanism Of Action R&D Progress IT-139 - Drug Profile Product Description Mechanism Of Action R&D Progress Rasolvir - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit GRP78 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Dormant Products 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Product Development Milestones Featured News & Press Releases Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer Mar 31, 2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012 Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339 Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Intezyne Technologies Inc, H1 2018 Pipeline by Nuevolution AB, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Intezyne Technologies Inc Nuevolution AB